MedTrace Logo

Effectiveness of CRD-740 in Heart Failure

NCT05409183 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-19

Study results available
· View outcomes & findings →

Summary

This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF.

Part B of the study was not conducted in favor of redesigned new studies.

Conditions

Interventions

DRUG

CRD-740

Tablets administered orally.

DRUG

Placebo

Tablets administered orally.

Sponsors & Collaborators

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Howard Surks, MD · Chief Medical and Scientific Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2023-05-02
Completion
2023-07-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Israel
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409183 on ClinicalTrials.gov